The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34269750/
Heterogeneity parameter was helpful for the accurate distinction of mediastinal lymph node metastasis in NSCLC. The combination of the SUVratio, Dmin and COV could improve the diagnostic accuracy. Multiple-parameters analysis...
Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34232984/
doi: 10.5858/arpa.2020-0376-OA. Online ahead of print. 1 From the Diagnostic and Experimental Pathology (Baker, Cannon, Holzer, Reising, Cook, Schade, Oakley III), Indianapolis, Indiana. 2 Diagnostic Medical Affairs (Sireci, Marella, Marquart),...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • Conclusion/Relevance: “Abbott Molecular break-apart FISH probes can be used to detect RET fusions. Laboratories can optimize cutoffs and/or testing algorithms to maximize sensitivity and specificity to ensure appropriate Show More
Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34235153/
Lung cancer is heterogeneous and challenging to cope with once it has progressed. Chemotherapy is the first step once no active driver mutation has been discovered. Non-antitumor drugs have been...
Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33924827/
Acute kidney injury is a common complication of many medical procedures, including those used in cancer treatment. Both chemotherapy and immunotherapy may result in deterioration of kidney function, which may...
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34178121/
In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.